Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure.

[1]  P. Ponikowski,et al.  Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo‐controlled trial , 2017, European journal of heart failure.

[2]  J. McMurray,et al.  Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the ASCEND‐HF trial , 2017, European journal of heart failure.

[3]  M. Böhm,et al.  Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease. , 2016, The American journal of cardiology.

[4]  M. Pan,et al.  Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. , 2016, International journal of cardiology.

[5]  M. Böhm,et al.  Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. , 2016, International journal of cardiology.

[6]  J. H. Patterson,et al.  Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial , 2016, European journal of heart failure.

[7]  K. Anstrom,et al.  Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). , 2016, Circulation. Heart failure.

[8]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[9]  C. Gaudio,et al.  Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Preliminary Randomized Prospective Study , 2016, Clinical Drug Investigation.

[10]  G. Filippatos,et al.  European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions , 2016, European journal of heart failure.

[11]  P. Ponikowski,et al.  Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT , 2016, European journal of heart failure.

[12]  K. Swedberg,et al.  Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post‐hoc analysis of SHIFT , 2016, European journal of heart failure.

[13]  M. Metra,et al.  [Heart rate and outcome in patients with acute and chronic heart failure]. , 2016, Giornale italiano di cardiologia.

[14]  M. S. Fernández,et al.  Clinical Experience with Ivabradine in Acute Heart Failure. , 2016 .

[15]  G. Filippatos,et al.  In-hospital management of acute heart failure: Practical recommendations and future perspectives. , 2015, International journal of cardiology.

[16]  J. McMurray,et al.  Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta‐analysis , 2015, European journal of heart failure.

[17]  J. Francis,et al.  Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[18]  Y. Cavusoglu,et al.  Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure , 2015, Journal of cardiovascular medicine.

[19]  L. Lund,et al.  Prognostic Significance of Resting Heart Rate and Use of &bgr;-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry , 2015, Circulation. Heart failure.

[20]  P. Kirchhof,et al.  Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data , 2015, BMJ : British Medical Journal.

[21]  G. Fonarow,et al.  Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. , 2015, Journal of the American College of Cardiology.

[22]  J. Camm,et al.  Twenty‐four‐hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy , 2015, European journal of heart failure.

[23]  Deepak L. Bhatt,et al.  Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization , 2015, Journal of the American Heart Association.

[24]  S. Solomon,et al.  Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. , 2015, European heart journal.

[25]  E. Braunwald.  The war against heart failure: the Lancet lecture , 2015, The Lancet.

[26]  B. Lattuca,et al.  Ivabradine: a promising drug in cardiogenic shock to prevent the undesirable sinus tachycardia induced by dobutamine? , 2015, International journal of cardiology.

[27]  Gabriel A. Koepp,et al.  Nitrate’s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Trial: Rationale and Design , 2015, Circulation. Heart failure.

[28]  P. Kirchhof,et al.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis , 2014, The Lancet.

[29]  M. Metra,et al.  Ivabradine during cardiogenic shock: a clinical case and review of the literature. , 2015, Heart & lung : the journal of critical care.

[30]  I. V. Van Gelder,et al.  Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[31]  R. McKelvie,et al.  Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve) , 2014, European journal of heart failure.

[32]  J. Bourke,et al.  Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials , 2014, Heart.

[33]  John G F Cleland,et al.  Is heart rate important for patients with heart failure in atrial fibrillation? , 2014, JACC. Heart failure.

[34]  L. Sargento,et al.  Heart Rate Reduction with Ivabradine in Patients with Acute Decompensated Systolic Heart Failure , 2014, American Journal of Cardiovascular Drugs.

[35]  P. Austin,et al.  Association of Heart Rate at Hospital Discharge With Mortality and Hospitalizations in Patients With Heart Failure , 2014, Circulation. Heart failure.

[36]  Adrian F Hernandez,et al.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.

[37]  C. Yancy,et al.  The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. , 2013, JACC. Heart failure.

[38]  H. Crijns,et al.  Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post‐hoc analysis of the RACE II study , 2013, European journal of heart failure.

[39]  T. Marwick,et al.  Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. , 2013, Journal of the American College of Cardiology.

[40]  J. Tardif,et al.  Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment? , 2013, Medical hypotheses.

[41]  R. Califf,et al.  Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?: Findings From ASCEND-HF , 2013, Circulation. Heart failure.

[42]  L. Køber,et al.  Resting, night-time, and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease. , 2013, European heart journal.

[43]  Deepak L. Bhatt,et al.  Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. , 2012, American heart journal.

[44]  L. Tavazzi,et al.  Multicenter Prospective Observational Study on Acute and Chronic Heart Failure: One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry , 2013, Circulation. Heart failure.

[45]  I. V. Van Gelder,et al.  Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). , 2013, Journal of the American College of Cardiology.

[46]  I. V. Van Gelder,et al.  Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. , 2013, JACC. Heart failure.

[47]  Robert O. Bonow,et al.  Rehospitalization for heart failure: problems and perspectives. , 2013, Journal of the American College of Cardiology.

[48]  M. Asakura,et al.  Extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes. , 2013, Journal of cardiology.

[49]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[50]  K. Swedberg,et al.  Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study , 2012, European heart journal.

[51]  Akshay S. Desai,et al.  Rehospitalization for heart failure: predict or prevent? , 2012, Circulation.

[52]  J. Cleland,et al.  Heart rate achieved or beta‐blocker dose in patients with chronic heart failure: which is the better target? , 2012, European journal of heart failure.

[53]  P. Ponikowski,et al.  The PROTECT in‐hospital risk model: 7‐day outcome in patients hospitalized with acute heart failure and renal dysfunction , 2012, European journal of heart failure.

[54]  K. Swedberg,et al.  Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. , 2012, Journal of the American College of Cardiology.

[55]  S. Solomon,et al.  Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. , 2012, Journal of the American College of Cardiology.

[56]  C. Tschöpe,et al.  Role of Heart Rate Reduction in the Prevention of Experimental Heart Failure: Comparison Between If-Channel Blockade and &bgr;-Receptor Blockade , 2012, Hypertension.

[57]  H. Crijns,et al.  The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. , 2011, Journal of the American College of Cardiology.

[58]  K. Swedberg,et al.  Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. , 2011, European Heart Journal.

[59]  P. Schnabel,et al.  Adjuvant Use of Ivabradine in Acute Heart Failure due to Myocarditis , 2011, Case reports in medicine.

[60]  L. Calò,et al.  Usefulness Of Ivabradine To Treat "unexpected" Heart Failure Caused By "acute" Right Ventricular Pacing , 2011, Indian pacing and electrophysiology journal.

[61]  K. Swedberg,et al.  Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy , 2011, European heart journal.

[62]  A. Wienke,et al.  Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the If (funny channel current) inhibitor ivabradine , 2011, Clinical Research in Cardiology.

[63]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[64]  E John Orav,et al.  Thirty-day readmission rates for Medicare beneficiaries by race and site of care. , 2011, JAMA.

[65]  J. Tardif,et al.  Heart Rate Reduction by Ivabradine Reduces Diastolic Dysfunction and Cardiac Fibrosis , 2011, Cardiology.

[66]  P. Heidenreich,et al.  Heart rate predicts mortality in patients with heart failure and preserved systolic function. , 2010, Journal of cardiac failure.

[67]  P. Ponikowski,et al.  EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot) , 2010, European journal of heart failure.

[68]  Michael Böhm,et al.  Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial , 2010, The Lancet.

[69]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[70]  W. Lepper,et al.  Cardiogenic Shock due to Tachycardiomyopathy after Heart Transplantation: Successful Treatment with Ivabradine , 2010, Cardiology.

[71]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[72]  Li Liang,et al.  A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program , 2010, Circulation. Cardiovascular quality and outcomes.

[73]  M. Böhm,et al.  Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure , 2009, Clinical Research in Cardiology.

[74]  F. Post,et al.  Ivabradin – eine neue Therapieoption bei kardiogenem Schock? , 2009, Herz Kardiovaskuläre Erkrankungen.

[75]  A. Capucci,et al.  Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[76]  E. Braunwald,et al.  Biomarkers in heart failure. , 2008, The New England journal of medicine.

[77]  D. Kass,et al.  Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction , 2006, Circulation.

[78]  B. Andersson,et al.  Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler‐echocardiographic study (SWEDIC) , 2004, European journal of heart failure.

[79]  W. Gaasch,et al.  Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. , 2004, The New England journal of medicine.

[80]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[81]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.

[82]  Harlan M Krumholz,et al.  Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.

[83]  Wang Ch,et al.  Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. , 2002 .

[84]  I. V. Van Gelder,et al.  Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. , 2000, European heart journal.

[85]  李永军,et al.  Atrial Fibrillation , 1999 .

[86]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[87]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[88]  H. Black,et al.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. , 1990, The American journal of cardiology.

[89]  R S Paffenbarger,et al.  Heart rate and cardiovascular mortality: the Framingham Study. , 1987, American heart journal.